This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis
by Zacks Equity Research
AbbVie (ABBV) files an application to the FDA, seeking its nod for a new indication of Rinvoq, which is active ankylosing spondylitis. The drug is already marketed to treat rheumatoid arthritis.
Teva Stock Down on Charges of Illegal Generic Price Fixing
by Zacks Equity Research
Teva (TEVA) has been indicted on charges of conspiring with other generic drugmakers to raise prices for generic drugs.
Novartis' Immunotherapy Fails in Late-Stage Skin Cancer Study
by Zacks Equity Research
Novartis' (NVS) phase III study evaluating the investigational immunotherapy, spartalizumab, in combination with the targeted therapies, Tafinlar and Mekinist, fails to achieve goals.
FDA Nods to Novartis' Kesimpta for Relapsing Forms of MS
by Zacks Equity Research
Novartis (NVS) gains an FDA nod for Kesimpta (ofatumumab) as a subcutaneous injection for relapsing multiple sclerosis. The drug is expected to be available early next month.
Pharma Stock Roundup: SNY, JNJ Acquisition Deals, FDA Approvals
by Kinjel Shah
J&J (JNJ) proposes to buy Momenta Pharmaceuticals while Sanofi (SNY) offers to buy Principia Biopharma
Glaxo Initiates Dosing in Phase III Meningitis Vaccine Study
by Zacks Equity Research
Glaxo (GSK) starts dosing with a phase III study on it 5-in-1 meningitis vaccine candidate.
PTC Therapeutics' Application for SMA Drug Accepted by EU
by Zacks Equity Research
PTC Therapeutics??? (PTCT) MAA for Evrysdi is accepted by the European Medicines Agency for the treatment of spinal muscular atrophy.
Roche's Xolair sBLA for Self Administration Accepted by FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) sBLA for a new self-administration option for Xolair across all approved U.S. indications.
AbbVie Outperforms Large-Cap Pharma Industry Year to Date
by Zacks Equity Research
AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.
CytoDyn Reports Top-Line Data From Phase II Coronavirus Study
by Zacks Equity Research
CytoDyn (CYDY) announces top-line results from a phase II study evaluating leronlimab in COVID-19 patients with mild-to-moderate symptoms.
Large-Cap Pharma Industry Outlook Dull Amid Coronavirus Woes
by Kinjel Shah
The Zacks Large-Cap Pharmaceuticals industry ranks in the bottom 26% of more than 250 Zacks industries.
Alzheimer's in Focus as Biogen's Aducanumab Gets Priority Tag
by Kinjel Shah
If Biogen's (BIIB) aducanumab is approved by the FDA, it will become the first medicine to be approved to reduce the clinical decline associated with Alzheimer's disease.
Alnylam (ALNY) Beats on Q2 Earnings, Narrows Sales Guidance
by Zacks Equity Research
Alnylam (ALNY) posts a narrower-than-expected loss in the second quarter of 2020 and sales miss estimates.
Bausch (BHC) Q2 Earnings & Revenues Miss Estimates, Down Y/Y
by Zacks Equity Research
Bausch (BHC) misses on earnings and sales in the second quarter and announces plans to spin off its eye care division.
Acceleron (XLRN) Reports Narrower-Than-Expected Q2 Loss
by Zacks Equity Research
Acceleron (XLRN) posts a narrower-than-expected Q2 loss owing to increased revenues.
Epizyme's (EPZM) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
Regeneron's (REGN) Q2 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on Q2 earnings and sales on solid performance of Dupixent and oncology drug, Libtayo.
Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi
by Zacks Equity Research
Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.
Genmab (GMAB) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Genmab's (GMAB) second-quarter revenues are likely to have been driven by royalties on sales of J&J's Darzalex. Several pipeline candidates are under development.
Pharma Stock Roundup: Q2 Earnings & J&J and PFE's Coronavirus Updates in Focus
by Kinjel Shah
Pfizer's (PFE) coronavirus vaccine candidate enters phase III. Several drugmakers announce second-quarter results.
Is a Beat in the Cards for Incyte's (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports second-quarter 2020 results.
The Zacks Analyst Blog Highlights: Facebook, Verizon Communications, Pfizer, Novartis and Philip Morris International
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Verizon Communications, Pfizer, Novartis and Philip Morris International
Top Research Reports for Facebook, Verizon & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Verizon Communications (VZ) and Pfizer (PFE).
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven second-quarter sales. Results will provide clarity on the impact of coronavirus on the company's business.
Pharma Stock Roundup: NVS, RHHBY Earnings, AZN, PFE Coronavirus Vaccine Early Data
by Kinjel Shah
Pfizer (PFE) and AstraZeneca (AZN) announce early data on their coronavirus vaccine candidates. Novartis (NVS) and Roche (RHHBY) announce second-quarter results.